Recomendaciones de la Sociedad Española de Reumatología sobre el tratamiento y uso de terapias sistémicas biológicas y no biológicas en artritis psoriásica

Moll, 1973, Psoriatic arthritis, Semin Arthritis Rheum., 3, 55, 10.1016/0049-0172(73)90035-8 Siegel, 2015, Targeting extra-articular manifestations in PsA: A closer look at enthesitis and dactylitis, Curr Opin Rheumatol., 27, 111, 10.1097/BOR.0000000000000155 Menter, 2009, Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents, J Am Acad Dermatol., 61, 451, 10.1016/j.jaad.2009.03.027 FitzGerald, 2015, Concepts of pathogenesis in psoriatic arthritis: Genotype determines clinical phenotype, Arthritis Res Ther., 17, 115, 10.1186/s13075-015-0640-3 Smolen, 2014, Proposal for a new nomenclature of disease-modifying antirheumatic drugs, Ann Rheum Dis., 73, 3, 10.1136/annrheumdis-2013-204317 Ash, 2012, A systematic literature review of drug therapies for the treatment of psoriatic arthritis: Current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis, Ann Rheum Dis., 71, 319, 10.1136/ard.2011.150995 Ramiro, 2016, Pharmacological treatment of psoriatic arthritis: A systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis, Ann Rheum Dis., 75, 490, 10.1136/annrheumdis-2015-208466 Olivieri, 2016, Psoriatic arthritis in 2015: Advancement continues in imaging, tight control and new drugs, Nat Rev Rheumatol., 12, 76, 10.1038/nrrheum.2015.184 Gossec, 2016, European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update, Ann Rheum Dis., 75, 499, 10.1136/annrheumdis-2015-208337 Coates, 2016, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis, Arthritis Rheumatol., 68, 1060 Fernández-Sueiro, 2011, Documento SER de consenso sobre el uso de terapias biológicas en la artritis psoriásica, Reumatol Clin., 7, 179, 10.1016/j.reuma.2011.02.001 Sociedad Española de Reumatología. Grupo de trabajo ESPOGUIA. Guía de práctica clínica para el tratamiento de la espondiloartritis axial y la artritis psoriásica. [monografía en Internet]. Madrid: Sociedad Española de Reumatología; 2015. D’Angelo, 2016, Improvements in diagnostic tools for early detection of psoriatic arthritis, Expert Rev Clin Immunol., 12, 1209, 10.1080/1744666X.2016.1193436 Durham, 2016, Psoriatic arthritis, Br J Hosp Med (Lond)., 77, C102, 10.12968/hmed.2016.77.7.C102 Queiro, 2017, Multidisciplinary care models for patients with psoriatic arthritis, Reumatol Clin., 13, 85, 10.1016/j.reuma.2016.03.005 Torre Alonso, 2017, Identification and management of comorbidity in psoriatic arthritis: Evidence- and expert-based recommendations from a multidisciplinary panel from Spain, Rheumatol Int., 37, 1239, 10.1007/s00296-017-3702-9 Di Minno, 2013, Obesity and the prediction of minimal disease activity: A prospective study in psoriatic arthritis, Arthritis Care Res (Hoboken)., 65, 141, 10.1002/acr.21711 Leeb, 2007, The Disease Activity Score in 28 joints in rheumatoid arthritis and psoriatic arthritis patients, Arthritis Rheum., 57, 256, 10.1002/art.22531 Mumtaz, 2011, Development of a preliminary composite disease activity index in psoriatic arthritis, Ann Rheum Dis., 70, 272, 10.1136/ard.2010.129379 Schoels, 2010, Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis, Ann Rheum Dis., 69, 1441, 10.1136/ard.2009.122259 Helliwell, 2013, The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project), Ann Rheum Dis., 72, 986, 10.1136/annrheumdis-2012-201341 Salaffi, 2014, Disease activity in psoriatic arthritis: Comparison of the discriminative capacity and construct validity of six composite indices in a real world, Biomed Res Int., 2014, 5281052014, 10.1155/2014/528105 Gladman, 2010, Composite measures in psoriatic arthritis: GRAPPA 2008, J Rheumatol., 37, 453, 10.3899/jrheum.090956 Helliwell, 2014, Composite disease activity and responder indices for psoriatic arthritis: A report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response, J Rheumatol., 41, 1212, 10.3899/jrheum.140172 Armstrong, 2014, Outcomes research in psoriasis and psoriatic arthritis using large databases and research networks: A report from the GRAPPA 2013 Annual Meeting, J Rheumatol., 41, 1233, 10.3899/jrheum.140178 Van den Bosch, 2015, Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations, J Rheumatol., 42, 952, 10.3899/jrheum.140312 Cantini, 2009, Criteria, frequency, and duration of clinical remission in psoriatic arthritis patients with peripheral involvement requiring second-line drugs, J Rheumatol Suppl., 83, 78, 10.3899/jrheum.090234 Cantini, 2008, Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs, Rheumatology (Oxford)., 47, 872, 10.1093/rheumatology/ken059 Coates, 2010, Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort, Arthritis Care Res (Hoboken)., 62, 970, 10.1002/acr.20162 Coates, 2010, Defining minimal disease activity in psoriatic arthritis: A proposed objective target for treatment, Ann Rheum Dis., 69, 48, 10.1136/ard.2008.102053 Tillett, 2015, Enhanced patient involvement and the need to revise the core set — Report from the Psoriatic Arthritis Working Group at OMERACT 2014, J Rheumatol., 42, 2198, 10.3899/jrheum.141156 Machado, 2014, Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis, Best Pract Res Clin Rheumatol., 28, 711, 10.1016/j.berh.2014.10.004 Healy, 2008, Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis, Arthritis Rheum., 59, 686, 10.1002/art.23568 Nell-Duxneuner, 2010, Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis, Ann Rheum Dis., 69, 546, 10.1136/ard.2009.117945 Coates, 2015, Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): A UK multicentre, open-label, randomised controlled trial, Lancet., 386, 2489, 10.1016/S0140-6736(15)00347-5 Coates, 2014, GRAPPA treatment recommendations: An update from the GRAPPA 2013 Annual Meeting, J Rheumatol., 41, 1237, 10.3899/jrheum.140179 Gonzalez-Juanatey, 2007, High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors, Arthritis Rheum., 57, 1074, 10.1002/art.22884 Jamnitski, 2013, Cardiovascular comorbidities in patients with psoriatic arthritis: A systematic review, Ann Rheum Dis., 72, 211, 10.1136/annrheumdis-2011-201194 Eder, 2015, Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis, Ann Rheum Dis., 74, 813, 10.1136/annrheumdis-2013-204448 Roubille, 2015, The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis, Ann Rheum Dis., 74, 480, 10.1136/annrheumdis-2014-206624 Tillett, 2013, Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis, Ann Rheum Dis., 72, 1358, 10.1136/annrheumdis-2012-202608 Gladman, 2011, Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?, Ann Rheum Dis., 70, 2152, 10.1136/ard.2011.150938 Haroon, 2015, Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis, Ann Rheum Dis., 74, 1045, 10.1136/annrheumdis-2013-204858 Theander, 2014, Early psoriatic arthritis: Short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA), Ann Rheum Dis., 73, 407, 10.1136/annrheumdis-2012-201972 Scarpa, 2008, The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: Results of a pilot randomised 6-month trial with methotrexate, Clin Rheumatol., 27, 823, 10.1007/s10067-007-0787-7 Kingsley, 2012, A randomized placebo-controlled trial of methotrexate in psoriatic arthritis, Rheumatology (Oxford)., 51, 1368, 10.1093/rheumatology/kes001 Lie, 2010, Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis, Ann Rheum Dis., 69, 671, 10.1136/ard.2009.113308 Goulabchand, 2014, Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials, Ann Rheum Dis., 73, 414, 10.1136/annrheumdis-2012-202641 Chandran, 2008, Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: Results from a longitudinal observational cohort, J Rheumatol., 35, 469 Schmitt, 2014, Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials, Br J Dermatol., 170, 274, 10.1111/bjd.12663 Schett, 2010, Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases, Ther Adv Musculoskelet Dis., 2, 271, 10.1177/1759720X10381432 Schett, 2012, Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study, Arthritis Rheum., 64, 3156, 10.1002/art.34627 Kavanaugh, 2014, Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor, Ann Rheum Dis., 73, 1020, 10.1136/annrheumdis-2013-205056 Kavanaugh, 2015, Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis, J Rheumatol., 42, 479, 10.3899/jrheum.140647 Crowley, 2017, Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2), J Am Acad Dermatol., 77, 310, 10.1016/j.jaad.2017.01.052 Kavanaugh, 2014, Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: Results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study), Ann Rheum Dis., 73, 1689, 10.1136/annrheumdis-2013-204902 Mease, 2014, Effect of certolizumab pegol over 48 weeks on signs and symptoms in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor exposure, Rheumatology (Oxford)., 53, i137, 10.1093/rheumatology/keu115.004 Mease, 2006, Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept, J Rheumatol., 33, 712 McInnes, 2013, Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial, Lancet., 382, 780, 10.1016/S0140-6736(13)60594-2 Ritchlin, 2014, Ann Rheum Dis., 73, 990, 10.1136/annrheumdis-2013-204655 Kavanaugh, 2014, Ann Rheum Dis., 73, 1000, 10.1136/annrheumdis-2013-204741 Van der Heijde, 2016, Brief Report: Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis, Arthritis Rheumatol., 68, 1914, 10.1002/art.39685 McInnes, 2015, Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial, Lancet., 386, 1137, 10.1016/S0140-6736(15)61134-5 Sanmartí, 2015, 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis, Reumatol Clin., 11, 279, 10.1016/j.reuma.2015.05.001 Behrens, 2015, Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: A systematic review of the literature, Rheumatology (Oxford)., 54, 915, 10.1093/rheumatology/keu415 Mease, 2005, Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial, Arthritis Rheum., 52, 3279, 10.1002/art.21306 Gladman, 2007, Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial, Arthritis Rheum., 56, 476, 10.1002/art.22379 Mease, 2004, Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression, Arthritis Rheum., 50, 2264, 10.1002/art.20335 Sterry, 2010, Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial, BMJ., 340, c147, 10.1136/bmj.c147 Combe, 2016, Comparison of etanercept monotherapy and combination therapy with methotrexate in psoriatic arthritis: Results from 2 clinical trials, J Rheumatol., 43, 1063, 10.3899/jrheum.151290 Kavanaugh, 2009, Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study, Arthritis Rheum., 60, 976, 10.1002/art.24403 Kavanaugh, 2013, Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: Results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study, Ann Rheum Dis., 72, 1777, 10.1136/annrheumdis-2012-202035 Antoni, 2005, Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT), Arthritis Rheum., 52, 1227, 10.1002/art.20967 Antoni, 2005, Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial, Ann Rheum Dis., 64, 1150, 10.1136/ard.2004.032268 Kavanaugh, 2007, Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: Results from the IMPACT 2 trial, Ann Rheum Dis., 66, 498, 10.1136/ard.2006.058339 Van der Heijde, 2007, Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2, Arthritis Rheum., 56, 2698, 10.1002/art.22805 Heiberg, 2008, The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study, Arthritis Rheum., 59, 234, 10.1002/art.23333 Fagerli, 2014, The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: Results from 440 patients included in the NOR-DMARD study, Ann Rheum Dis., 73, 132, 10.1136/annrheumdis-2012-202347 Glintborg, 2011, Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: Results from the nationwide Danish DANBIO registry, Arthritis Rheum., 63, 382, 10.1002/art.30117 Hoa, 2013, Comparing adalimumab and etanercept as first line agents in patients with psoriatic arthritis: data from the Rheumadata_ clinical database and registry [abstract], Arthritis Rheum., 65, S145 Mease, 2014, Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA), Ann Rheum Dis., 73, 48, 10.1136/annrheumdis-2013-203696 Mease, 2015, Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis, N Engl J Med., 373, 1329, 10.1056/NEJMoa1412679 Fagerli, 2013, Switching between TNF inhibitors in psoriatic arthritis: Data from the NOR-DMARD study, Ann Rheum Dis., 72, 1840, 10.1136/annrheumdis-2012-203018 Glintborg, 2013, Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: Results from the Danish Nationwide DANBIO Registry, Arthritis Rheum., 65, 1213, 10.1002/art.37876 Kristensen, 2016, Effectiveness and feasibility associated with switching to a second or third TNF inhibitor in patients with psoriatic arthritis: A cohort study from Southern Sweden, J Rheumatol., 43, 81, 10.3899/jrheum.150744 Soubrier, 2015, Treatment response, drug survival and safety of anti-tumour necrosis factor alpha therapy in 193 patients with psoriatic arthritis: a twelve-year «real life» experience, Joint Bone Spine., 82, 31, 10.1016/j.jbspin.2014.08.001 Coates, 2008, Sustained response to long-term biologics and switching in psoriatic arthritis: Results from real life experience, Ann Rheum Dis., 67, 717, 10.1136/ard.2007.082925 Ruwaard, 2015, Efficacy of switching tumor necrosis factor α inhibitor to a second tumor necrosis factor α inhibitor and the influence of drug levels and anti-drug antibodies in patients with ankylosing spondylitis and psoriatic arthritis, Ann Rheum Dis., 74, 271, 10.1136/annrheumdis-2015-eular.2351 Gladman, 2010, Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: Effectiveness and safety results from an open-label study, J Rheumatol., 37, 1898, 10.3899/jrheum.100069 Genovese, 2014, Efficacy and safety of brodalumab over one year in patients with psoriatic arthritis with and without prior exposure to a biologic, Ann Rheum Dis., 73, 1052, 10.1136/annrheumdis-2014-eular.1499 Orbai, 2014, Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis, J Rheumatol., 41, 2290, 10.3899/jrheum.140878 Rose, 2014, Comprehensive treatment of dactylitis in psoriatic arthritis, J Rheumatol., 41, 2295, 10.3899/jrheum.140879 Juanola Roura, 2011, [Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in spondyloarthritis except for psoriatic arthritis], Reumatol Clin., 7, 113, 10.1016/j.reuma.2010.12.002 Pathan, 2013, Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis, Ann Rheum Dis., 72, 1475, 10.1136/annrheumdis-2012-201915 Baeten, 2015, Secukinumab, an Interleukin-17A inhibitor, in ankylosing spondylitis, N Engl J Med., 373, 2534, 10.1056/NEJMoa1505066 Kavanaugh, 2016, Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: Post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2), Ann Rheum Dis., 75, 1984, 10.1136/annrheumdis-2015-209068 Baraliakos, 2014, Continuous long-term i-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis, Ann Rheum Dis., 73, 710, 10.1136/annrheumdis-2012-202698 Haroon, 2013, The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis, Arthritis Rheum., 65, 2645 Daudén, 2016, Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology, J Eur Acad Dermatol Venereol., 30, 1, 10.1111/jdv.13542 Husni, 2015, Comorbidities in psoriatic arthritis, Rheum Dis Clin North Am., 41, 677, 10.1016/j.rdc.2015.07.008 González-Álvaro, 2015, Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, Rheumatology (Oxford)., 54, 1200, 10.1093/rheumatology/keu461 Helliwell, 2014, Qualifying unmet needs and improving standards of care in psoriatic arthritis, Arthritis Care Res (Hoboken)., 66, 1759, 10.1002/acr.22404 Abad Hernández MÁ, 2015, Position paper from the Spanish Society of Rheumatology on biosimilar drugs, Reumatol Clin., 11, 269